Primary hyperoxaluria;Hiperoxaluria primaria

Nefrologia

Volumn 34, Issue 3, 2014, Pages 398-412

  Lorenzo, Víctor ^a   Torres, Armando ^a   Salido, Eduardo ^b  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

Hyperoxaluric states; Liver renal transplantation; Oxalosis; Primary hiperoxaluria; Renal lithiasis

Indexed keywords

CLASSIFICATION; HUMAN; HYPEROXALURIA, PRIMARY;

HUMANS; HYPEROXALURIA, PRIMARY;

EID: 84901318410     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2014.Jan.12335     Document Type: Review

References (132)

1. Cochat P, Rumsby G. Primary Hyperoxaluria. N Engl J Med 2013;369(7):649-58.
2. Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias. Kidney Int 2009;75(12):1264-71.
3. Leumann E, Hoppe B. The primary hyperoxalurias. J Am Soc Nephrol 2001;12(9):1986-93.
4. Salido E, Pey AL, Rodriguez R, Lorenzo V. Primary hyperoxalurias: disorders of glyoxylate detoxification. Biochim Biophys Acta 2012;1822(9):1453-64.
5. van Woerden CS, GroothoffJW, Wanders RJ, Davin JC, Wijburg FA. Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome. Nephrol Dial Transplant 2003;18(2):273-9.
6. Cochat P, Deloraine A, Rotily M, Olive F, Liponski I, Deries N. Epidemiology of primary hyperoxaluria type 1. Societe de Nephrologie and the Societe de Nephrologie Pediatrique. Nephrol Dial Transplant 1995;10 Suppl 8:3-7.
7. Lorenzo V, Alvarez A, Torres A, Torregrosa V, Hernandez D, Salido E. Presentation and role of transplantation in adult patients with type 1 primary hyperoxaluria and the I244T AGXT mutation: Single-center experience. Kidney Int 2006;70(6):1115-9.
8. Harambat J, Van Stralen KJ, Espinosa L, GroothoffJW, Hulton SA, Cerkauskiene R, et al. Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. Clin J Am Soc Nephrol 2012;7(3):458-65.
9. Williams AW, Wilson DM. Dietary intake, absorption, metabolism, and excretion of oxalate. Semin Nephrol 1990;10(1):2-8.
10. Wanders RJ, Waterham HR. Peroxisomal disorders: the single peroxisomal enzyme deficiencies. Biochim Biophys Acta 2006;1763(12):1707-20.
11. Knight J, Jiang J, Assimos DG, Holmes RP. Hydroxyproline ingestion and urinary oxalate and glycolate excretion. Kidney Int 2006;70(11):1929-34.
12. Hoppe B. An update on primary hyperoxaluria. Nat Rev Nephrol 2012;8(8):467-75.
13. Hoppe B, Leumann E, Von UG, Laube N, Hesse A. Diagnostic and therapeutic approaches in patients with secondary hyperoxaluria. Front Biosci 2003;8:e437-43.
14. Danpure CJ, Rumsby G. Molecular aetiology of primary hyperoxaluria and its implications for clinical management. Expert Rev Mol Med 2004;6(1):1-16.
15. Harambat J, Fargue S, Bacchetta J, Acquaviva C, Cochat P. Primary hyperoxaluria. Int J Nephrol 2011;2011:864580.
16. Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, Seide BM, et al. Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol 2011;6(9):2289-95.
17. Danpure CJ. Molecular aetiology of primary hyperoxaluria type 1. Nephron Exp Nephrol 2004;98(2):e39-44.
18. Danpure CJ. Molecular etiology of primary hyperoxaluria type 1: new directions for treatment. Am J Nephrol 2005;25(3):303-10.
19. Salido E, Pey AL, Rodriguez R, Lorenzo V. Primary hyperoxalurias: disorders of glyoxylate detoxification. Biochim Biophys Acta 2012;1822(9):1453-64.
20. Santana A, Torres A, Salido E. [Molecular pathology of primary hyperoxaluria]. Nefrologia 2003;23 Suppl 1:90-7.
21. Cellini B, Bertoldi M, Montioli R, Paiardini A, Borri VC. Human wild-type alanine:glyoxylate aminotransferase and its naturally occurring G82E variant: functional properties and physiological implications. Biochem J 2007;408(1):39-50.
22. Cellini B, Montioli R, Voltattorni CB. Human liver peroxisomal alanine:glyoxylate aminotransferase: characterization of the two allelic forms and their pathogenic variants. Biochim Biophys Acta 2011;1814(11):1577-84.
23. Santana A, Salido E, Torres A, Shapiro LJ. Primary hyperoxaluria type 1 in the Canary Islands: a conformational disease due to I244T mutation in the P11L-containing alanine:glyoxylate aminotransferase. Proc Natl Acad Sci U S A 2003;100(12):7277-82.
24. Williams EL, Acquaviva C, Amoroso A, Chevalier F, Coulter-Mackie M, Monico CG, et al. Primary hyperoxaluria type 1: update and additional mutation analysis of the AGXT gene. Hum Mutat 2009;30(6):910-7.
25. Danpure CJ. Primary hyperoxaluria type 1: AGT mistargeting highlights the fundamental differences between the peroxisomal and mitochondrial protein import pathways. Biochim Biophys Acta 2006;1763(12):1776-84.
26. Danpure CJ, Cooper PJ, Wise PJ, Jennings PR. An enzyme trafficking defect in two patients with primary hyperoxaluria type 1: peroxisomal alanine/glyoxylate aminotransferase rerouted to mitochondria. J Cell Biol 1989;108(4):1345-52.
27. Purdue PE, Allsop J, Isaya G, Rosenberg LE, Danpure CJ. Mistargeting of peroxisomal L-alanine:glyoxylate aminotransferase to mitochondria in primary hyperoxaluria patients depends upon activation of a cryptic mitochondrial targeting sequence by a point mutation. Proc Natl Acad Sci U S A 1991;88(23):10900-4.
28. Danpure CJ, Purdue PE, Fryer P, Griffiths S, Allsop J, Lumb MJ, et al. Enzymological and mutational analysis of a complex primary hyperoxaluria type 1 phenotype involving alanine:glyoxylate aminotransferase peroxisome-to-mitochondrion mistargeting and intraperoxisomal aggregation. Am J Hum Genet 1993;53(2):417-32.
29. Williams EL, Kemper MJ, Rumsby G. A de novo mutation in the AGXT gene causing primary hyperoxaluria type 1. Am J Kidney Dis 2006;48(3):481-3.
30. Seargeant LE, DeGroot GW, Dilling LA, Mallory CJ, Haworth JC. Primary oxaluria type 2 (L-glyceric aciduria): a rare cause of nephrolithiasis in children. J Pediatr 1991;118(6):912-4.
31. Dobbins JW, Binder HJ. Effect of bile salts and fatty acids on the colonic absorption of oxalate. Gastroenterology 1976;70(6):1096-100.
32. Bobrowski AE, Langman CB. Hyperoxaluria and systemic oxalosis: current therapy and future directions. Expert Opin Pharmacother 2006;7(14):1887-96.
33. Caspary WF. Enteric hyperoxaluria. N Engl J Med 1977;296(23):1357.
34. Caspary WF. Intestinal oxalate absorption. I. Absorption in vitro. Res Exp Med (Berl) 1977;171(1):13-24.
35. Dobbins JW, Binder HJ. Importance of the colon in enteric hyperoxaluria. N Engl J Med 1977;296(6):298-301.
36. Earnest DL. Enteric hyperoxaluria. Adv Intern Med 1979;24:407-27.
37. Diamond KL, Fox CC, Barch DH. Role of cecal pH in intestinal oxalate absorption in the rat. J Lab Clin Med 1988;112(3):352-6.
38. Canos HJ, Hogg GA, Jeffery JR. Oxalate nephropathy due to gastrointestinal disorders. Can Med Assoc J 1981;124(6):729-33.
39. Hofmann AF, Schmuck G, Scopinaro N, Laker MF, Sherr HP, Lorenzo D, et al. Hyperoxaluria associated with intestinal bypass surgery for morbid obesity: occurrence, pathogenesis and approaches to treatment. Int J Obes 1981;5(5):513-8.
40. Hofmann AF, Laker MF, Dharmsathaphorn K, Sherr HP, Lorenzo D. Complex pathogenesis of hyperoxaluria after jejunoileal bypass surgery. Oxalogenic substances in diet contribute to urinary oxalate. Gastroenterology 1983;84(2):293-300.
41. Lindsjo M, Danielson BG, Fellstrom B, Lithell H, Ljunghall S. Intestinal absorption of oxalate and calcium in patients with jejunoileal bypass. Scand J Urol Nephrol 1989;23(4):283-9.
42. Terribile M, Capuano M, Cangiano G, Carnovale V, Ferrara P, Petrarulo M, et al. Factors increasing the risk for stone formation in adult patients with cystic fibrosis. Nephrol Dial Transplant 2006;21(7):1870-5.
43. Cuvelier C, Goffin E, Cosyns JP, Wauthier M, de Strihou CY. Enteric hyperoxaluria: a hidden cause of early renal graft failure in two successive transplants: spontaneous late graft recovery. Am J Kidney Dis 2002;40(1):E3.
44. Mole DR, Tomson CR, Mortensen N, Winearls CG. Renal complications of jejuno-ileal bypass for obesity. QJM 2001;94(2):69-77.
45. Moller T, Muller G, Schutte W, Rogos R, Schneider W. [Oxalic acid resorption in patients with resection of the small intestine, jejunoileal bypass, Crohn disease and chronic pancreatitis]. Dtsch Z Verdau Stoffwechselkr 1987;47(3):113-8.
46. Nelson WK, Houghton SG, Milliner DS, Lieske JC, Sarr MG. Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: potentially serious and unappreciated complications of Roux-en-Y gastric bypass. Surg Obes Relat Dis 2005;1(5):481-5.
47. Hoppe B, Beck B, Gatter N, Von Unruh G, Tischer A, Hesse A, et al. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int 2006;70(7):1305-11.
48. Kruse JA. Methanol and ethylene glycol intoxication. Crit Care Clin 2012;28(4):661-711.
49. Pomara C, Fiore C, D'Errico S, Riezzo I, Fineschi V. Calcium oxalate crystals in acute ethylene glycol poisoning: a confocal laser scanning microscope study in a fatal case. Clin Toxicol (Phila) 2008;46(4):322-4.
50. Samarneh MM, Shtaynberg N, Goldman M, Epstein E, Kleiner M, El-Sayegh S. Severe oxalosis with systemic manifestations. J Clin Med Res 2012;4(1):56-60.
51. Simpson GL, Ortwerth BJ. The non-oxidative degradation of ascorbic acid at physiological conditions. Biochim Biophys Acta 2000;1501(1):12-24.
52. Canavese C, Petrarulo M, Massarenti P, Berutti S, Fenoglio R, Pauletto D, et al. Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients. Am J Kidney Dis 2005;45(3):540-9.
53. Wong K, Thomson C, Bailey RR, McDiarmid S, Gardner J. Acute oxalate nephropathy after a massive intravenous dose of vitamin C. Aust N Z J Med 1994;24(4):410-1.
54. Nasr SH, Kashtanova Y, Levchuk V, Markowitz GS. Secondary oxalosis due to excess vitamin C intake. Kidney Int 2006;70(10):1672.
55. Cochat P, Hulton SA, Acquaviva C, Danpure CJ, Daudon M, De Marchi M, et al. Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant 2012;27(5):1729-36.
56. Skinner R, Tomson CR, Tapson JS. Long term survival on haemodialysis in primary hyperoxaluria. Int J Artif Organs 1990;13(7):412-5.
57. van Woerden CS, GroothoffJW, Wijburg FA, Waterham HR, Wanders RJ, Janssen MJ, et al. Primary hyperoxaluria remains undiagnosed in patients with hyperoxaluria and recurrent urolithiasis. Clin Chem 2007;53(8):1553-5.
58. Milliner DS, Wilson DM, Smith LH. Phenotypic expression of primary hyperoxaluria: comparative features of types I and II. Kidney Int 2001;59(1):31-6.
59. Belostotsky R, Seboun E, Idelson GH, Milliner DS, Becker-Cohen R, Rinat C, et al. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet 2010;87(3):392-9.
60. Cochat P, Fargue S, Bacchetta J, Bertholet-Thomas A, Sabot JF, Harambat J. [Primary hyperoxaluria]. Nephrol Ther 2011;7(4):249-59.
61. Lorenz EC, Michet CJ, Milliner DS, Lieske JC. Update on oxalate crystal disease. Curr Rheumatol Rep 2013;15(7):340.
62. Hoppe B, Kemper MJ, Bokenkamp A, Portale AA, Cohn RA, Langman CB. Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure. Kidney Int 1999;56(1):268-74.
63. Marangella M, Petrarulo M, Vitale C, Daniele PG, Sammartano S, Cosseddu D, et al. Serum calcium oxalate saturation in patients on maintenance haemodialysis for primary hyperoxaluria or oxalosisunrelated renal diseases. Clin Sci (Lond) 1991;81(4):483-90.
64. Marangella M, Cosseddu D, Petrarulo M, Vitale C, Linari F. Thresholds of serum calcium oxalate supersaturation in relation to renal function in patients with or without primary hyperoxaluria. Nephrol Dial Transplant 1993;8(12):1333-7.
65. Lorenzo V, Torres A, Hernandez D. Evolución de la enfermedad ósea en pacientes con hiperoxaluria primaria. Nefrologia 1990;1:53-60.
66. Baethge BA, Sanusi ID, Landreneau MD, Rohr MS, McDonald JC. Livedo reticularis and peripheral gangrene associated with primary hyperoxaluria. Arthritis Rheum 1988;31(9):1199-203.
67. Gherardi G, Poggi A, Sisca S, Calderaro V, Bonucci E. Bone oxalosis and renal osteodystrophy. Arch Pathol Lab Med 1980;104(2):105-11.
68. Julian BA, Faugere MC, Malluche HH. Oxalosis in bone causing a radiographical mimicry of renal osteodystrophy. Am J Kidney Dis 1987;9(5):436-40.
69. Lorenzo V, Hernandez D, Dominguez M, Rodriguez A, Torres A. Oxalosis as a cause of absolute resistance to rHuEpo in chronic haemodialysis patients. Nephrol Dial Transplant 1992;7(11):1163-4.
70. Sahin G, Acikalin MF, Yalcin AU. Erythropoietin resistance as a result of oxalosis in bone marrow. Clin Nephrol 2005;63(5):402-4.
71. Daudon M, Jungers P, Bazin D. Peculiar morphology of stones in primary hyperoxaluria. N Engl J Med 2008;359(1):100-2.
72. Rumsby G. An overview of the role of genotyping in the diagnosis of the primary hyperoxalurias. Urol Res 2005;33(5):318-20.
73. Milliner DS. The primary hyperoxalurias: an algorithm for diagnosis. Am J Nephrol 2005;25(2):154-60.
74. Marangella M, Petrarulo M, Bianco O, Vitale C, Finocchiaro P, Linari F. Glycolate determination detects type I primary hyperoxaluria in dialysis patients. Kidney Int 1991;39(1):149-54.
75. Dietzen DJ, Wilhite TR, Kenagy DN, Milliner DS, Smith CH, Landt M. Extraction of glyceric and glycolic acids from urine with tetrahydrofuran: utility in detection of primary hyperoxaluria. Clin Chem 1997;43(8 Pt 1):1315-20.
76. Barratt TM, Kasidas GP, Murdoch I, Rose GA. Urinary oxalate and glycolate excretion and plasma oxalate concentration. Arch Dis Child 1991;66(4):501-3.
77. Marangella M, Petrarulo M, Cosseddu D, Vitale C, Linari F. Oxalate balance studies in patients on hemodialysis for type I primary hyperoxaluria. Am J Kidney Dis 1992;19(6):546-53.
78. Pey AL, Salido E, Sanchez-Ruiz JM. Role of low native state kinetic stability and interaction of partially unfolded states with molecular chaperones in the mitochondrial protein mistargeting associated with primary hyperoxaluria. Amino Acids 2011;41(5):1233-45.
79. Purdue PE, Lumb MJ, Fox M, Griffo G, Hamon-Benais C, Povey S, et al. Characterization and chromosomal mapping of a genomic clone encoding human alanine:glyoxylate aminotransferase. Genomics 1991;10(1):34-42.
80. Takada Y, Kaneko N, Esumi H, Purdue PE, Danpure CJ. Human peroxisomal L-alanine: glyoxylate aminotransferase. Evolutionaryloss of a mitochondrial targeting signal by point mutation of the initiation codon. Biochem J 1990;268(2):517-20.
81. Rumsby G, Weir T, Samuell CT. A semiautomated alanine:glyoxylate aminotransferase assay for the tissue diagnosis of primary hyperoxaluria type 1. Ann Clin Biochem 1997;34(Pt 4):400-4.
82. Danpure CJ, Jennings PR, Fryer P, Purdue PE, Allsop J. Primary hyperoxaluria type 1: genotypic and phenotypic heterogeneity. J Inherit Metab Dis 1994;17(4):487-99.
83. Rumsby G. Experience in prenatal diagnosis of primary hyperoxaluria type 1. J Nephrol 1998;11 Suppl 1:13-4.
84. Scheinman JI. Primary hyperoxaluria: therapeutic strategies for the 90's. Kidney Int 1991;40(3):389-99.
85. Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 1996;155(3):839-43.
86. Leumann E, Hoppe B, Neuhaus T. Management of primary hyperoxaluria: efficacy of oral citrate administration. Pediatr Nephrol 1993;7(2):207-11.
87. Rodgers A, Allie-Hamdulay S, Jackson G. Therapeutic action of citrate in urolithiasis explained by chemical speciation: increase in pH is the determinant factor. Nephrol Dial Transplant 2006;21(2):361-9.
88. Marangella M, Bagnis C, Bruno M, Vitale C, Petrarulo M, Ramello A. Crystallization inhibitors in the pathophysiology and treatment of nephrolithiasis. Urol Int 2004;72 Suppl 1:6-10.
89. Pak CY, Heller HJ, Pearle MS, Odvina CV, Poindexter JR, Peterson RD. Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions. J Urol 2003;169(2):465-9.
90. Milliner DS, Eickholt JT, Bergstralh EJ, Wilson DM, Smith LH. Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N Engl J Med 1994;331(23):1553-8.
91. Zimmermann DJ, Voss S, von Unruh GE, Hesse A. Importance of magnesium in absorption and excretion of oxalate. Urol Int 2005;74(3):262-7.
92. Marangella M, Vitale C, Cosseddu D, Petrarulo M, Linari F. Effects of oral and intravenous calcitriol on serum calcium oxalate saturation in dialysis patients. Clin Sci (Lond) 1993;85(3):309-14.
93. von Unruh GE, Voss S, Sauerbruch T, Hesse A. Dependence of oxalate absorption on the daily calcium intake. J Am Soc Nephrol 2004;15(6):1567-73.
94. Hatch M, Freel RW. The roles and mechanisms of intestinal oxalate transport in oxalate homeostasis. Semin Nephrol 2008;28(2):143-51.
95. Grujic D, Salido EC, Shenoy BC, Langman CB, McGrath ME, Patel RJ, et al. Hyperoxaluria is reduced and nephrocalcinosis prevented with an oxalate-degrading enzyme in mice with hyperoxaluria. Am J Nephrol 2009;29(2):86-93.
96. Hoppe B, GroothoffJW, Hulton SA, Cochat P, Niaudet P, Kemper MJ, et al. Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrol Dial Transplant 2011;26(11):3609-15.
97. Lieske JC, Goldfarb DS, De Simone C, Regnier C. Use of a probiotic to decrease enteric hyperoxaluria. Kidney Int 2005;68(3):1244-9.
98. Campieri C, Campieri M, Bertuzzi V, Swennen E, Matteuzzi D, Stefoni S, et al. Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney Int 2001;60(3):1097-105.
99. Hatch M, Cornelius J, Allison M, Sidhu H, Peck A, Freel RW. Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int 2006;69(4):691-8.
100. Hoppe B, Latta K, Von Schnakenburg, Kemper MJ. Primary hyperoxaluria--the German experience. Am J Nephrol 2005;25(3):276-81.
101. Harambat J, Fargue S, Acquaviva C, Gagnadoux MF, Janssen F, Liutkus A, et al. Genotype-phenotype correlation in primary hyperoxaluria type 1: the p. Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int 2010;77(5):443-9.
102. Monico CG, Rossetti S, Olson JB, Milliner DS. Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int 2005;67(5):1704-9.
103. Monico CG, Olson JB, Milliner DS. Implications of genotype and enzyme phenotype in pyridoxine response of patients with type I primary hyperoxaluria. Am J Nephrol 2005;25(2):183-8.
104. Van Woerden CS, GroothoffJW, Wijburg FA, Annink C, Wanders RJ, Waterham HR. Clinical implications of mutation analysis in primary hyperoxaluria type 1. Kidney Int 2004;66(2):746-52.
105. Straub M, Gschwend J, Zorn C. Pediatric urolithiasis: the current surgical management. Pediatr Nephrol 2010;25(7):1239-44.
106. Kerbl K, Clayman RV. Endourologic treatment of nephrocalcinosis. Urology 2000;56(3):508.
107. Illies F, Bonzel KE, Wingen AM, Latta K, Hoyer PF. Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. Kidney Int 2006;70(9):1642-8.
108. Watts RW, Veall N, Purkiss P. Oxalate dynamics and removal rates during haemodialysis and peritoneal dialysis in patients with primary hyperoxaluria and severe renal failure. Clin Sci (Lond) 1984;66(5):591-7.
109. Marangella M, Bagnis C, Bruno M, Petrarulo M, Gabella P, Linari F. Determinants of oxalate balance in patients on chronic peritoneal dialysis. Am J Kidney Dis 1993;21(4):419-26.
110. Yamauchi T, Quillard M, Takahashi S, Nguyen-Khoa M. Oxalate removal by daily dialysis in a patient with primary hyperoxaluria type 1. Nephrol Dial Transplant 2001;16(12):2407-11.
111. Cochat P, Liutkus A, Fargue S, Basmaison O, Ranchin B, Rolland MO. Primary hyperoxaluria type 1: still challenging! Pediatr Nephrol 2006;21(8):1075-81.
112. Cibrik DM, Kaplan B, Arndorfer JA, Meier-Kriesche HU. Renal allograft survival in patients with oxalosis. Transplantation 2002;74(5):707-10.
113. Bergstralh EJ, Monico CG, Lieske JC, Herges RM, Langman CB, Hoppe B, et al. Transplantation outcomes in primary hyperoxaluria. Am J Transplant 2010;10(11):2493-501.
114. Scheinman JI, Najarian JS, Mauer SM. Successful strategies for renal transplantation in primary oxalosis. Kidney Int 1984;25(5):804-11.
115. Cochat P, Fargue S, Harambat J. Primary hyperoxaluria type 1: strategy for organ transplantation. Curr Opin Organ Transplant 2010;15(5):590-3.
116. Watts RW, Morgan SH, Danpure CJ, Purkiss P, Calne RY, Rolles K, et al. Combined hepatic and renal transplantation in primary hyperoxaluria type I: clinical report of nine cases. Am J Med 1991;90(2):179-88.
117. Cibrik DM, Kaplan B, Arndorfer JA, Meier-Kriesche HU. Renal allograft survival in patients with oxalosis. Transplantation 2002;74(5):707-10.
118. Harps E, Brinkert F, Ganschow R, Briem-Richter A, van Husen M, Schmidtke S, et al. Immediate postoperative intensive care treatmentof pediatric combined liver-kidney transplantation: outcome and prognostic factors. Transplantation 2011;91(10):1127-31.
119. Jamieson NV. A 20-year experience of combined liver/kidney transplantation for primary hyperoxaluria (PH1): the European PH1 transplant registry experience 1984-2004. Am J Nephrol 2005;25(3):282-9.
120. Mehrabi A, Fonouni H, Ayoub E, Rahbari NN, Müller SA, Morath Ch, et al. A single center experience of combined liver kidney transplantation. Clin Transplant 2009;23 Suppl 21:102-14.
121. Monico CG, Milliner DS. Combined liver-kidney and kidneyalone transplantation in primary hyperoxaluria. Liver Transpl 2001;7(11):954-63.
122. Kemper MJ, Nolkemper D, Rogiers X, Timmermann K, Sturm E, Malago M, et al. Preemptive liver transplantation in primary hyperoxaluria type 1: timing and preliminary results. J Nephrol 1998;11 Suppl 1:46-8.
123. Cochat P, Faure JL, Divry P, Danpure CJ, Descos B, Wright C, et al. Liver transplantation in primary hyperoxaluria type 1. Lancet 1989;1(8647):1142-3.
124. Perera MT, Sharif K, Lloyd C, Foster K, Hulton SA, Mirza DF, et al. Pre-emptive liver transplantation for primary hyperoxaluria (PH-I) arrests long-term renal function deterioration. Nephrol Dial Transplant 2011;26(1):354-9.
125. Brinkert F, Ganschow R, Helmke K, Harps E, Fischer L, Nashan B, et al. Transplantation procedures in children with primary hyperoxaluria type 1: outcome and longitudinal growth. Transplantation 2009;87(9):1415-21.
126. Cochat P, GroothoffJ. Primary hyperoxaluria type 1: practical and ethical issues. Pediatr Nephrol 2013;28(12):2273-81.
127. Salido EC, Li XM, Lu Y, Wang X, Santana A, Roy-Chowdhury N, et al. Alanine-glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer. Proc Natl Acad Sci U S A 2006;103(48):18249-54.
128. Salido E, Rodriguez-Pena M, Santana A, Beattie SG, Petry H, Torres A. Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer. Mol Ther 2011;19(5):870-5.
129. Powers ET, Morimoto RI, Dillin A, Kelly JW, Balch WE. Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem 2009;78:959-91.
130. Albert A, Yunta C, Arranz R, Peña A, Salido E, Valpuesta JM, et al. Structure of GroEL in complex with an early folding intermediate of alanine glyoxylate aminotransferase. J Biol Chem 2010;285(9):6371-6.
131. Guha C, Yamanouchi K, Jiang J, Wang X, Roy Chowdhury N, Santana A, et al. Feasibility of hepatocyte transplantationbased therapies for primary hyperoxalurias. Am J Nephrol 2005;25(2):161-70.
132. Jiang J, Salido EC, Guha C, Wang X, Moitra R, Liu L, et al. Correction of hyperoxaluria by liver repopulation with hepatocytes in a mouse model of primary hyperoxaluria type-1. Transplantation 2008;85(9):1253-60.